SEC Filing Form 4

This filing details transactions by Edris Badreddin, a director at Edgewise Therapeutics, Inc. On June 5, 2026, Badreddin was granted 5,619 Restricted Stock Units (RSUs) and 8,188 Stock Options. The RSUs vest 100% on June 5, 2027, or the business day before the 2027 annual meeting. The Stock Options also vest 100% on June 5, 2027, or the business day before the 2027 annual meeting. Both transactions are reported as direct ownership. The exercise price for the stock options is $35.59.